TAVR Advances, Medication Safety, and Diabetes Prevention Insights
In this episode, Dr. Chi-Ming Chow provides an in-depth overview of the PARTNER 2A trial, comparing Transcatheter Aortic Valve Replacement (TAVR) with Surgical Aortic Valve Replacement (SAVR), discussing the challenges, advancements, and outcomes in TAVR technology. He addresses medication management transformation, highlighting the complexities and errors in the refill process using the Swiss Cheese Model, and explores ways to reduce these errors through system improvements. The episode also examines long-term data from the Diabetes Prevention Program (DPP) trial, comparing lifestyle changes versus metformin in addressing multimorbidity and chronic conditions, and discusses the generalizability and benefits of DPP interventions.
Key Points
- The 10-year follow-up of the PARTNER 2A trial revealed a higher all-cause mortality rate and increased incidence of aortic valve reinterventions in the TAVR group compared to the SAVR group, highlighting some limitations of the Sapien XT device.
- Advancements in TAVR technology, such as the third-generation Sapien 3 device, have shown more reassuring long-term outcomes, emphasizing the importance of procedural improvements and updated device designs.
- The Diabetes Prevention Program trial demonstrated that lifestyle interventions significantly reduced the risk of developing multiple chronic conditions in individuals with prediabetes over a 21-year period, whereas metformin did not show the same benefit.
Chapters
| 0:00 | |
| 1:27 | |
| 3:37 | |
| 4:47 | |
| 6:19 | |
| 6:40 | |
| 7:12 | |
| 9:56 | |
| 12:00 |
Transcript
Loading transcript...